Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

About this update from Nuvectis Pharma, Inc.

[{"type":"image","alt":"Nuvectis Pharma, Inc.","displaySize":"","headline":null,"caption":"Nuvectis Pharma, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":152,"url":"https://media.zenfs.com/en/globenewswire.com/989394dc1a2c2d302d391f5a4d69410d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/W.V.VnmdN5OtxNT977ZzKg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIxMztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/989394dc1a2c2d302d391f5a4d69410d","width":300,"height":152}},"lazy":false},{"type":"text","content":"Fort Lee, NJ, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced upcoming poster presentations for NXP900 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics taking place October 22-26, 2025 in Boston, MA.","length":466,"tagName":"p"},{"type":"table","headerItems":[],"items":[{"val":[{"style":"width:62.52%;border-top:solid black 1pt;border-bottom:solid black 1pt;text-align:justify;vertical-align:middle;vertical-align:top;","val":[{"type":"text","content":"Titles and Presenters","length":21,"tagName":"p","attribs":{}}]},{"style":"width:37.48%;vertical-align:middle;text-align:left;padding-left:25.0px;border-top:solid black 1pt;border-bottom:solid black 1pt;text-align:justify;vertical-align:middle;vertical-align:top;","val":[{"type":"text","content":"Presentation Details","length":20,"tagName":"p","attribs":{}}]}]},{"val":[{"style":"width:62.52%;border-bottom:solid black 1pt;vertical-align:top;","val":[{"type":"text","content":"Title Clinical safety, pharmacokinetics, pharmacodynamics, and cytochrome P450 interactions for the SRC/YES1 kinase inhibitor NXP900Presenter Gerald Falchook, MD Sarah Cannon Research Institute at HealthOne Denver, CO, United States.","length":240,"tagName":"p","attribs":{}}]},{"style":"width:37.48%;vertical-align:middle;text-align:left;padding-left:25.0px;border-bottom:solid black 1pt;vertical-align:top;","val":[{"type":"text","content":"Session Poster Session APoster Number LB-A019Session Date / Time October 23, 2025 12:30 – 4 pm ET","length":106,"tagName":"p","attribs":{}}]}]},{"val":[{"style":"width:62.52%;border-bottom:soli...

More updates from Nuvectis Pharma, Inc.